Zoetis has announced the European launch of Cytopoint, a single-injection therapy that addressed the clinical signs of atopic dermatitis in dogs.
The first monoclonal antibody approved for veterinary use in the EU, the drug targets and neutralises the canine interleukin-31 protein that triggers itching. It is administered once-monthly and provides fast, long-lasting relief from itching, inflammation and lesions.
“Zoetis has announced the launch of Cytopoint, the first monoclonal antibody approved for veterinary use in the EU.“
Clinical trials have shown that Cytopoint can deliver clear benefits in the reduction of itching and disease severity, as evaluated by scoring skin lesions.
Itching is among the most frequent canine health complaints, affecting around one in six dogs whose owners seek veterinary help. Approximately 15 to 20 percent of all itchy dogs are eventually diagnosed with atopic dermatitis.
It marks the second product to be produced through a new research and development platform created by Zoetis, following Apoquel, a tablet-based treatment also designed to tackle canine atopic dermatitis.
Dr Andy Hillier, veterinary specialty operations and medical lead for allergy and dermatology at Zoetis, said: "Veterinary surgeons have told us that allergic dogs and their owners have a variety of needs and we are proud to offer them two innovative solutions with Cytopoint and our oral tablet therapy, Apoquel."
With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Animal Health